Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an EP-CAM-/CD3-bispecific antibody

International Journal of Cancer

Volumn 105, Issue 2, 2003, Pages 241-248

  Wimberger, Pauline ^a   Xiang, Wei ^b   Mayr, Doris ^b   Diebold, Joachim ^b   Dreier, Torsten ^c   Baeuerle, Patrick A ^c   Kimmig, Rainer ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c MICROMET AG   (Germany)

Author keywords

Bispecific antibody; Ep CAM; Ex vivo tumor cell lysis; Ovarian cancer; T cell recruitment

Indexed keywords

ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CA 125 ANTIGEN; CELL ADHESION MOLECULE; EPITHELIAL CELL ADHESION MOLECULE ANTIBODY; MONOCLONAL ANTIBODY CD3; OKT 3; PROPIDIUM IODIDE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SELECTION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; ISOTOPE LABELING; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD3; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL SURVIVAL; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0242684481     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11056     Document Type: Article

References (46)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1997;46:5-27.
2. du Bois A, Richter B, Warm M, Costa S, Bauknecht T, Lück HJ, Meier W, Möbus V. For the AGO Study Group: cisplatin/paclitaxel vs. carboplatin/paclitaxel as first-line treatment in ovarian cancer. Proc Am Soc Clin Oncol 1998;17:1395.
3. Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999;21:309-18.
4. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20:1S-13S.
5. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against their targets. Nat Med 2000;6:443-6.
6. Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;6:1788-94.
7. Kreitman RJ. Immunotoxins in cancer therapy. Curr Opin Immunol. 1999;11:570-8.
8. Carter P. Improving the efficacy of antibody-based cancer therapies. Nat Rev 2001;1:118-29.
9. Staerz UD, Bevan MJ. Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T cell activity. Proc Natl Acad Sci USA 1986;83:1453-7.
10. Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies antibody in cancer therapy. Curr Opin Immunol 1999;11:558-62.
11. Withoff S, Helfrich W, de Leij LF, Molema G. Bi-specific antibody therapy for the treatment of cancer. Curr Opin Mol Ther 2001;3:53-62.
12. Talac R, Nelson H. Current perspectives of bispecific antibody-based immunotherapy. J Biol Regul Homeost Agents 2000;14:175-81.
13. McCall AM, Shahied L, Amoroso AR, Horak EM, Simmons HH, Nielson U, Adams GP, Schier R, Marks JD, Weiner LM. Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 2001;166:6112-7.
14. + natural-killer-like T lymphocytes to Ep-CAM-expressing tumor cells. Cancer Immunol Immunother 2000;49:441-8.
15. Gruber M, Schodin BA, Wilson ER, Kranz DM. Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in Escherichia coli. J Immunol 1994;152:5368-74.
16. Löffter A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dorken B, Bargou RC. A recombinant bispecific single chain antibody, CD19 × CD3, induces rapid and high lymphoma - directed cytotoxicity by unstimulated T lymphocytes. Blood 2000;95:2098-103.
17. Mack M, Gruber R, Schmidt S, Riethmüller G, Kufer P. Biologic properties of a bispecific single-chain antibody directed against 17-1A (Ep-CAM) and CD3. J Immunol 1997;158:3965-70.
18. Maletz K, Kufer P, Mack M, Raum T, Pantel K, Riethmuller G, Gruber R. Bispecific single-chain antibodies as effective tools for elimination of epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity. Int J Cancer 2001;93:409-16.
19. Marme A, Strauss G, Bastert G, Grischke EM, Moldenhauer G. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer 2002;101:183-9.
20. Smans KA, Ingvarsson MB, Lindgren P, Canevari S, Walt H, Stigbrand T, Backstrom T, Millan JL. Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens. Int J Cancer 1999;83:270-7.
21. Miotti S, Negri DR, Valora O, Calabrese M, Bolhuis RL, Gratama JW, Colnaghi MI, Canevari S. Level of anti-mouse-antibody response induced by bispecific monoclonal antibody OC/TR in ovarian carcinoma patients is associated with longer survival. Int J Cancer 1999;84:62-8.
22. Mack M, Riethmüller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci 1995;92:7021-5.
23. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med 2000;77:699-712.
24. McLaughlin PM, Harmsen MC, Dokter WH, Kroesen BJ, van der Mo Brinker MG, Hollema H, Ruiters MH, Buys CH, de Leij LF. The epithelial glycoprotein 2 (EGP-2) promoter-driven epithelial-specific expression of EGP-2 in transgenic mice: a model to study carcinoma-directed immunotherapy. Cancer Res 2001;15:4105-11.
25. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO. Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res 1998;4:295-302.
26. Poczatek RB, Myers RB, Manne U, Oelschlager DK, Weiss HL, Bostwick DG, Grizzle WE. Ep-CAM levels in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. J Urol 1999;162:1462-6.
27. Gastl G, Spizzo G, Obrist P, Dünser M, Mikuz G. Ep-AM overexpression in breast cancer as a predictor of survival. Lancet 2000;1981-2.
28. De Bree R, Roos JC, Quak JJ, Den Hollander W, Snow GB, Van Dongen GA. Clinical screening of monoclonal antibodies 323/A3, cSF-25 and K928 for suitability of targeting tumours in the upper aerodigestive and respiratory tract. Nucl Med Commun 1994;15:613-27.
29. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmüller G, Bargou R, Baeuerle PA. Extremely potent, rapid and costimulation-independent cytotoxic T cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002;100:690-7.
30. Eisenthal A, Polyvkin N, Bramante-Schreiber L, Misonznik F, Hassner A, Lifschitz-Mercer B. Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Hum Pathol 2001;32:803-7.
31. Yokota T, Milenic E, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison of other immunoglobulin forms. Cancer Res. 1992;52:3402-8.
32. Sears HF, Atkinson B, Mattis J, Ernst C, Herlyn D, Steplewski Z, Hayry P, Koprowski H. Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours. Lancet 1982;1:762-5.
33. Holz E, Gruber R, Riethmüller G. Monoclonal antibodies in cancer therapy. New perspectives after the colorectal carcinoma trial. Clin Immunother 1996;5:214-22.
34. Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994;343:1177-83.
35. Punt CJ, Nagy A, Douillard J, Figer A, Skovsgaard T, Monson J, Barone C, Jones D, Dethling J, Coleman J. Edrecolomab (17-1° antibody) alone or in combination with 5-fluorouracil based chemotherapy in the adjuvant treatment of Stage III colon cancer: results from a Phase III study. Proc ASCO 2001; abstr no. 487.
36. Morris A. Modification of histocompatibility antigen expression in cells expressing activated oncogenes: implications for tumour development. Anticancer Res 1990;10:1161-7.
37. Rees RC, Mian S. Selective MHC expression in tumours adaptive and innate antitumor responses. Cancer Immunol Immunother 1999;48:374-81.
38. Mingari MC, Ponte M, Vitale C, Bellomo R, Moretta L. Expression of HLA Class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T cell activation and function. Hum Immunol 2000;61:44-50.
39. Ritz U, Seliger B. The transporter associated with antigen processing (TAP): structural integrity, expression, function, and its clinical relevance. Mol Med 2001;7:149-58.
40. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Riethmüller G, Segurdo OG. Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993;151:4209-20.
41. Schendel DJ. On the peptide model of all recognition: cytotoxic T lymphocytes recognize an alloantigen encoded by two HLA-linked genes. Hum Immunol 1990;27:229-39.
42. Schendel DJ, Oberneder R, Falk CS, Jantzer P, Kressenstein S, Maget B, Hofstetter A, Riethmüller G, Nossner E. Cellular and molecular oncology of major histocompatibility complex (MHC) restricted, and non MHC-restricted effector recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J Mol Med 1997;75:400-13.
43. Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, Davis MM, Shaw AS, Allen PM, Dustin ML. The immunological synapse. Annu Rev Immunol 2001;19:375-96.
44. Tuosto L, Parolini I, Schroder S, Sargiacomo M, Lnzavecchia A, Viola A. Organization of plasma membrane functional rafts upon T cell activation. Eur J Immunol 2001;31:345-9.
45. Roovers RC, van der Linden E, de Bruine AP, Arends JW, Hoogenboom HR. In vitro characterization of a monovalent and bivalent form of a fully human anti Ep-CAM phage antibody. Cancer Immunol Immunother 2001;50:51-9.
46. Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (αEp-CAM × αCD3). J Histochem Cytochem 2001;49:911-7.